Who
Amy L. Burroughs
Director
Company insider
Files Form 4 as: Director, Tenaya Therapeutics; Chief Executive Officer, Terns Pharmaceuticals; Director, DiaMedica Therapeutics.
In numbers
- Trades disclosed
- 77
- Buys
- 4
- Sells
- 4
- Bought
- $345K
- Sold
- $13.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 15 Jul 2021
- Last trade
- 28 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 28 May 2026filed 29 May 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Code U | $7.8M146,614 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Code U | $441K8,319 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $8.0M150,000 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —955,534 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,250,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —300,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —955,534 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,250,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —300,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticals | SEC FORM 4 Code U | $7.8M146,614 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticals | SEC FORM 4 Code U | $441K8,319 at $53.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticals | SEC FORM 4 Code D | $8.0M150,000 at $53.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $68K14,583 at $4.64 | filing |
| 16 Mar 2026filed 17 Mar 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $550K11,813 at $46.57 | filing |
| 16 Mar 2026filed 17 Mar 2026 | Terns PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $131K2,770 at $47.30 | filing |
| 16 Mar 2026filed 17 Mar 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —14,583 at $0.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,583 at $0.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | Terns Pharmaceuticals | SEC FORM 4 Code M | $68K14,583 at $4.64 | filing |
News
No headline names them, or the companies they trade most, lately.